Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma

BackgroundDysregulated long non-coding RNAs (lncRNAs) have been found to have oncogenic and/or tumor suppressive roles in the development and progression of cancer, implying their potentials as novel independent biomarkers for cancer diagnosis and prognosis. However, the prognostic significance of expression profile-based lncRNA signature for outcome prediction in patients with multiple myeloma (MM) has not yet been investigated.MethodsLncRNA expression profiles of a large cohort of patients with MM were obtained and analyzed by repurposing the publically available microarray data. An lncRNA-focus risk score model was developed from the training dataset, and then validated in the testing and another two independent external datasets. The time-dependent receiver operating characteristic (ROC) curve was used to evaluate the prognostic performance for survival prediction. The biological function of prognostic lncRNAs was predicted using bioinformatics analysis.ResultsFour lncRNAs were identified to be significantly associated with overall survival (OS) of patients with MM in the training dataset, and were combined to develop a four-lncRNA prognostic signature to stratify patients into high-risk and low-risk groups. Patients of training dataset in the high-risk group exhibited shorter OS than those in the low-risk group (HR = 2.718, 95 % CI = 1.937-3.815, p <0.001). The similar prognostic values of four-lncRNA signature were observed in the testing dataset, entire GSE24080 dataset and another two independent external datasets. Multivariate Cox regression and stratified analysis showed that the prognostic power of four-lncRNA signature was independent of clinical features, including serum beta 2-microglobulin (Sβ2M), serum albumin (ALB) and lactate dehydrogenase (LDH). ROC analysis also demonstrated the better performance for predicting 3-year OS. Functional enrichment analysis suggested that these four lncRNAs may be involved in known genetic and epigenetic events linked to MM.ConclusionsOur results demonstrated potential application of lncRNAs as novel independent biomarkers for diagnosis and prognosis in MM. These lncRNA biomarkers may contribute to the understanding of underlying molecular basis of MM.

[1]  Cole Trapnell,et al.  Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. , 2011, Genes & development.

[2]  T. Casci.  Mouse models: A double hit for diabetes , 2003, Nature Reviews Genetics.

[3]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[4]  D Puthier,et al.  High incidence of N and K‐Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis , 2001, Human mutation.

[5]  A. Fatica,et al.  Long non-coding RNAs: new players in cell differentiation and development , 2013, Nature Reviews Genetics.

[6]  Ping Chen,et al.  Upregulation of lncRNA MEG3 Promotes Osteogenic Differentiation of Mesenchymal Stem Cells From Multiple Myeloma Patients By Targeting BMP4 Transcription , 2015, Stem cells.

[7]  J. Mattick,et al.  Long non-coding RNAs: insights into functions , 2009, Nature Reviews Genetics.

[8]  T. Chevassut,et al.  The Genetic Architecture of Multiple Myeloma , 2014, Advances in hematology.

[9]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. Zhan,et al.  Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. , 2003, Blood.

[11]  Sarah Geisler,et al.  RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts , 2013, Nature Reviews Molecular Cell Biology.

[12]  S. Dimmeler,et al.  Long Noncoding RNAs in Cardiovascular Diseases , 2015, Circulation research.

[13]  Denise P Barlow,et al.  Gene regulation by the act of long non-coding RNA transcription , 2013, BMC Biology.

[14]  M. Rue,et al.  Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.

[15]  J. Rinn,et al.  A Large Intergenic Noncoding RNA Induced by p53 Mediates Global Gene Repression in the p53 Response , 2010, Cell.

[16]  M. Mourtada-Maarabouni,et al.  GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer , 2009, Oncogene.

[17]  C. Sotiriou,et al.  Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? , 2007, Nature Reviews Cancer.

[18]  Ji-Lin Wang,et al.  A long non-coding RNA signature to improve prognosis prediction of colorectal cancer , 2014, Oncotarget.

[19]  International Human Genome Sequencing Consortium.  Finishing the euchromatic sequence of the human genome , 2004 .

[20]  Haixiu Yang,et al.  A potential signature of eight long non-coding RNAs predicts survival in patients with non-small cell lung cancer , 2015, Journal of Translational Medicine.

[21]  P A Ward,et al.  Molecular signatures of sepsis: multiorgan gene expression profiles of systemic inflammation. , 2001, The American journal of pathology.

[22]  Michael Thomas,et al.  MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer , 2003, Oncogene.

[23]  Wing Hung Wong,et al.  SeqMap: mapping massive amount of oligonucleotides to the genome , 2008, Bioinform..

[24]  Laurence Lodé,et al.  Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Glavač,et al.  Long Non-Coding RNA in Cancer , 2013, International journal of molecular sciences.

[26]  Howard Y. Chang,et al.  Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis , 2010, Nature.

[27]  J. Mattick,et al.  Long noncoding RNAs and the genetics of cancer , 2013, British Journal of Cancer.

[28]  William Stafford Noble,et al.  Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project , 2007, Nature.

[29]  Anthony Boral,et al.  Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. , 2006, Blood.

[30]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.

[31]  C. Ponting,et al.  Evolution and Functions of Long Noncoding RNAs , 2009, Cell.

[32]  Francesca D. Ciccarelli,et al.  NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes , 2014, Database J. Biol. Databases Curation.

[33]  Yunli Zhou,et al.  MEG3 noncoding RNA: a tumor suppressor. , 2012, Journal of molecular endocrinology.

[34]  Zhen Su,et al.  Integrative genomic analyses reveal clinically relevant long non-coding RNA in human cancer , 2013 .

[35]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[36]  J. Bonfield,et al.  Finishing the euchromatic sequence of the human genome , 2004, Nature.

[37]  Howard Y. Chang,et al.  Long intergenic noncoding RNAs: new links in cancer progression. , 2011, Cancer research.

[38]  Jan-Gowth Chang,et al.  MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression , 2014, BMC Cancer.

[39]  Catherine Baxter.  Cancer genetics: Molecular signatures , 2003, Nature Reviews Genetics.

[40]  Bronwen L. Aken,et al.  GENCODE: The reference human genome annotation for The ENCODE Project , 2012, Genome research.

[41]  Jin Meng,et al.  A four-long non-coding RNA signature in predicting breast cancer survival , 2014, Journal of experimental & clinical cancer research : CR.

[42]  Jingyuan Fu,et al.  Human Disease-Associated Genetic Variation Impacts Large Intergenic Non-Coding RNA Expression , 2013, PLoS genetics.

[43]  Xiaoqin Zhang,et al.  A long non-coding RNA signature in glioblastoma multiforme predicts survival , 2013, Neurobiology of Disease.

[44]  Fang Zhou,et al.  LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma , 2014, Gut.

[45]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[46]  Maqc Consortium.  The MicroArray Quality Control ( MAQC )-II study of common practices for the development and validation of microarray-based predictive models , 2012 .

[47]  Gareth J. Morgan,et al.  A gene expression signature for high-risk multiple myeloma , 2012, Leukemia.